Personalized Whole-Brain Spectroscopy Guided Mapping for Tumor Treating Fields in Adult Glioblastoma Patients

What this Trial Is About

Researchers are studying patients with Glioblastoma GBM who will begin treatment with Optune, a novel therapy using tumor treating fields TTFields, also known as electrical therapy. This study evaluates whether a more precise method of mapping the Optune arrays, guided by advanced whole brain MRI spectroscopy, can improve treatment outcomes by better targeting tumor cells compared to the standard mapping based on regular MRI. The goal is to enhance tumor cell killing, reduce local recurrence, and improve overall survival and quality of life. Participants in the study are randomly assigned to one of two groups one group receives TTFields mapping based on standard MRI imaging, while the other group receives mapping created using advanced MRI techniques including whole brain spectroscopy. Although all participants undergo whole brain spectroscopy imaging at MRI study time points, only the experimental group uses this advanced imaging to guide their Optune array layout. The study uses a parallel design with triple masking to compare both mapping methods. Participants will be monitored over time with assessments every 2 months to measure the time to tumor progression. Researchers will also follow overall survival and clinical outcomes for up to 5 years. During the study, participants undergo multiple MRI scans including spectroscopy sequences and receive TTFields treatment according to their assigned mapping method. The study aims to collect detailed diagnostic and outcome data while tracking safety and quality of life throughout this period.

WBSI Guided Personalized Delivery of TTFields